tradingkey.logo

Haleon PLC

HLN
9.830USD
+0.310+3.26%
Close 12/15, 16:00ETQuotes delayed by 15 min
88.32BMarket Cap
40.16P/E TTM

Haleon PLC

9.830
+0.310+3.26%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Haleon PLC

Currency: USD Updated: 2025-12-12

Key Insights

Haleon PLC's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 72/159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 10.58.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Haleon PLC's Score

Industry at a Glance

Industry Ranking
72 / 159
Overall Ranking
182 / 4592
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Analyst Rating

Based on 4 analysts
Buy
Current Rating
10.579
Target Price
+12.54%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Haleon PLC Highlights

StrengthsRisks
Haleon plc is a consumer healthcare company. The Company’s product portfolio spans six major categories, including oral health, vitamins, minerals and supplements (VMS), pain relief, respiratory health, digestive health and therapeutic skin health and other. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA) & LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company’s oral health brands include Sensodyne, Polident, and Parodontax. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, Flonase, Contac, and Beechams. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Benefiber. Its therapeutic skin health brands include Fenistil, Zovirax, and Bactroban.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 8.92B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 41.40%.
Undervalued
The company’s latest PE is 38.90, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 570.14M shares, decreasing 2.78% quarter-over-quarter.
Held by Murray Stahl
Star Investor Murray Stahl holds 14.08K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.10.

Financial Health

Currency: USD Updated: 2025-12-12

The current financial score of Haleon PLC is 8.65, ranking 48/159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high.

Score

Industry at a Glance

Previous score
8.65
Change
0

Financials

6.05

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

10.00

Operational Efficiency

10.00

Growth Potential

10.00

Shareholder Returns

7.21

Haleon PLC's Company Valuation

Currency: USD Updated: 2025-12-12

The current valuation score of Haleon PLC is 4.63, ranking 157/159 in the Pharmaceuticals industry. Its current P/E ratio is 38.90, which is 193.10% below the recent high of 114.00 and 8.40% above the recent low of 35.63.

Score

Industry at a Glance

Previous score
4.63
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 72/159
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2025-12-12

The current earnings forecast score of Haleon PLC is 8.00, ranking 56/159 in the Pharmaceuticals industry. The average price target for Haleon PLC is 11.50, with a high of 13.44 and a low of 5.88.

Score

Industry at a Glance

Previous score
8.00
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 4 analysts
Buy
Current Rating
10.579
Target Price
+12.54%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

171
Total
6
Median
8
Average
Company name
Ratings
Analysts
Haleon PLC
HLN
4
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Vertex Pharmaceuticals Inc
VRTX
33
Eli Lilly and Co
LLY
33
AbbVie Inc
ABBV
32
1
2
3
...
34

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-12-12

The current price momentum score of Haleon PLC is 6.94, ranking 96/159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 9.87 and the support level at 9.24, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
7.10
Change
-0.16

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(1)
Neutral(3)
Buy(1)
Indicators
Value
Direction
MACD(12,26,9)
-0.017
Neutral
RSI(14)
58.986
Neutral
STOCH(KDJ)(9,3,3)
64.998
Buy
ATR(14)
0.174
High Vlolatility
CCI(14)
92.174
Neutral
Williams %R
15.873
Overbought
TRIX(12,20)
0.007
Sell
StochRSI(14)
100.000
Overbought
Moving Average
Sell(1)
Neutral(0)
Buy(5)
Indicators
Value
Direction
MA5
9.542
Buy
MA10
9.534
Buy
MA20
9.622
Buy
MA50
9.431
Buy
MA100
9.463
Buy
MA200
9.926
Sell

Institutional Confidence

Currency: USD Updated: 2025-12-12

The current institutional shareholding score of Haleon PLC is 3.00, ranking 92/159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 12.80%, representing a quarter-over-quarter decrease of 0.43%. The largest institutional shareholder is Van Duyn Dodge & E. Morris Cox, holding a total of 154.38M shares, representing 3.47% of shares outstanding, with 7.78% decrease in holdings.

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
155.47M
-8.09%
Fidelity Management & Research Company LLC
97.52M
+0.37%
ClearBridge Investments, LLC
31.45M
-3.52%
Harding Loevner LP
22.55M
-2.26%
Wellington Management Company, LLP
13.09M
-0.93%
Fidelity Institutional Asset Management
14.24M
-0.37%
Sculptor Capital Management, Inc
9.95M
-8.30%
Managed Account Advisors LLC
10.98M
+127.05%
Douglas C. Lane & Associates
8.18M
-5.01%
Aristotle Capital Management, LLC
8.20M
-2.86%
1
2

Risk Assessment

Currency: USD Updated: 2025-12-12

The current risk assessment score of Haleon PLC is 9.65, ranking 5/159 in the Pharmaceuticals industry. The company's beta value is 0.20. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
9.65
Change
0
Beta vs S&P 500 index
0.20
VaR
--
240-Day Maximum Drawdown
+23.58%
240-Day Volatility
+23.98%

Return

Best Daily Return
60 days
+3.26%
120 days
+3.26%
5 years
--
Worst Daily Return
60 days
-3.13%
120 days
-4.13%
5 years
--
Sharpe Ratio
60 days
+1.30
120 days
-0.57
5 years
--

Risk Assessment

Maximum Drawdown
240 days
+23.58%
3 years
+23.58%
5 years
--
Return-to-Drawdown Ratio
240 days
+0.14
3 years
+0.33
5 years
--
Skewness
240 days
-0.35
3 years
-0.02
5 years
--

Volatility

Realised Volatility
240 days
+23.98%
5 years
--
Standardised True Range
240 days
+1.77%
5 years
--
Downside Risk-Adjusted Return
120 days
-97.85%
240 days
-97.85%
Maximum Daily Upside Volatility
60 days
+18.39%
Maximum Daily Downside Volatility
60 days
+17.84%

Liquidity

Average Turnover Rate
60 days
+0.13%
120 days
+0.15%
5 years
--
Turnover Deviation
20 days
+10.37%
60 days
+48.08%
120 days
+72.91%

Peer Comparison

Pharmaceuticals
Haleon PLC
Haleon PLC
HLN
7.11 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals PLC
JAZZ
8.88 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Prestige Consumer Healthcare Inc
Prestige Consumer Healthcare Inc
PBH
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Collegium Pharmaceutical Inc
Collegium Pharmaceutical Inc
COLL
8.69 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals Inc
CPRX
8.63 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
United Therapeutics Corp
UTHR
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more

FAQs

How does TradingKey generate the Stock Score of Haleon PLC?

The TradingKey Stock Score provides a comprehensive assessment of Haleon PLC based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Haleon PLC’s performance and outlook.

How do we generate the financial health score of Haleon PLC?

To generate the financial health score of Haleon PLC, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Haleon PLC's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Haleon PLC.

How do we generate the company valuation score of Haleon PLC?

To generate the company valuation score of Haleon PLC, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Haleon PLC’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Haleon PLC’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Haleon PLC.

How do we generate the earnings forecast score of Haleon PLC?

To calculate the earnings forecast score of Haleon PLC, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Haleon PLC’s future.

How do we generate the price momentum score of Haleon PLC?

When generating the price momentum score for Haleon PLC, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Haleon PLC’s prices. A higher score indicates a more stable short-term price trend for Haleon PLC.

How do we generate the institutional confidence score of Haleon PLC?

To generate the institutional confidence score of Haleon PLC, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Haleon PLC’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Haleon PLC.

How do we generate the risk management score of Haleon PLC?

To assess the risk management score of Haleon PLC, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Haleon PLC’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Haleon PLC.
KeyAI